Xenon Pharmaceuticals Debt to Equity Ratio 2012-2022 | XENE

Current and historical debt to equity ratio values for Xenon Pharmaceuticals (XENE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Xenon Pharmaceuticals debt/equity for the three months ending March 31, 2022 was 0.00.
Xenon Pharmaceuticals Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2022-03-31 $0.02B $0.54B 0.03
2021-12-31 $0.02B $0.55B 0.04
2021-09-30 $0.02B $0.25B 0.06
2021-06-30 $0.02B $0.26B 0.07
2021-03-31 $0.01B $0.28B 0.05
2020-12-31 $0.02B $0.17B 0.10
2020-09-30 $0.02B $0.18B 0.09
2020-06-30 $0.02B $0.19B 0.11
2020-03-31 $0.05B $0.19B 0.26
2019-12-31 $0.06B $0.09B 0.61
2019-09-30 $0.02B $0.08B 0.33
2019-06-30 $0.02B $0.08B 0.28
2019-03-31 $0.02B $0.09B 0.24
2018-12-31 $0.02B $0.10B 0.19
2018-09-30 $0.02B $0.11B 0.17
2018-06-30 $0.02B $0.05B 0.29
2018-03-31 $0.01B $0.03B 0.33
2017-12-31 $0.01B $0.04B 0.28
2017-09-30 $0.00B $0.04B 0.07
2017-06-30 $0.00B $0.05B 0.08
2017-03-31 $0.00B $0.06B 0.06
2016-12-31 $0.00B $0.06B 0.06
2016-09-30 $0.00B $0.07B 0.06
2016-06-30 $0.00B $0.05B 0.06
2016-03-31 $0.00B $0.06B 0.05
2015-12-31 $0.00B $0.06B 0.05
2015-09-30 $0.01B $0.06B 0.09
2015-06-30 $0.01B $0.06B 0.19
2015-03-31 $0.02B $0.06B 0.27
2014-12-31 $0.02B $0.07B 0.20
2014-09-30 $0.02B $0.04B 0.55
2014-06-30 $0.00B $0.00B 0.00
2014-03-31 $0.00B $0.00B 0.00
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B $0.00B 0.00
2012-12-31 $0.05B $0.01B 4.02
2011-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.548B $0.018B
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00